[HTML][HTML] Fibrinolysis for patients with intermediate-risk pulmonary embolism

G Meyer, E Vicaut, T Danays, G Agnelli… - … England Journal of …, 2014 - Mass Medical Soc
Background The role of fibrinolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. Methods In a randomized, double-blind trial, we compared …

[HTML][HTML] Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction

…, P Goldstein, R Wilcox, T Danays… - … England Journal of …, 2013 - Mass Medical Soc
Background It is not known whether prehospital fibrinolysis, coupled with timely coronary
angiography, provides a clinical outcome similar to that with primary percutaneous coronary …

[HTML][HTML] Thrombolysis during resuscitation for out-of-hospital cardiac arrest

…, E Bluhmki, A Belmans, T Danays… - … England Journal of …, 2008 - Mass Medical Soc
Background Approximately 70% of persons who have an out-of-hospital cardiac arrest have
underlying acute myocardial infarction or pulmonary embolism. Therefore, thrombolysis …

Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism

SV Konstantinides, E Vicaut, T Danays… - Journal of the American …, 2017 - jacc.org
Background : The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is
unknown. Objectives : This study investigated the long-term prognosis of patients with …

Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction

P Tanswell, N Modi, D Combs, T Danays - Clinical pharmacokinetics, 2002 - Springer
Tenecteplase is a novel fibrinolytic protein bioengineered from human tissue plasminogen
activator (alteplase) for the therapy of acute ST-segment elevation myocardial infarction. …

The strategic reperfusion early after myocardial infarction (STREAM) study

…, A Gershlick, P Goldstein, R Wilcox, T Danays… - American heart …, 2010 - Elsevier
BACKGROUND: Primary percutaneous coronary intervention (PCI) has emerged as the
preferred therapy for acute ST-elevation myocardial infarction (STEMI) provided it is performed …

ST–segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: strategic reperfusion …

…, P Goldstein, R Wilcox, Y Lambert, T Danays… - Circulation, 2014 - Am Heart Assoc
Background— In the Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial,
a pharmaco-invasive (PI) strategy was compared with primary percutaneous coronary …

Alteplase for acute ischemic stroke in patients aged> 80 years: pooled analyses of individual patient data

E Bluhmki, T Danays, G Biegert, W Hacke, KR Lees - Stroke, 2020 - Am Heart Assoc
Background/Purpose: Expert guidelines specify no upper age limit for alteplase for thrombolysis
of acute ischemic stroke (AIS) but, until recently, European regulatory criteria restricted …

[HTML][HTML] Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the …

…, H Bouvaist, F Couturaud, T Danays… - Clinical Research in …, 2019 - Springer
Methods In a post hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial, we
focused on 219 survivors of acute intermediate-risk PE with clinical and echocardiographic …

STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment–elevation myocardial infarction: a randomized …

…, K Bogaerts, CM Westerhout, A Pagès, T Danays… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: ST-segment–elevation myocardial infarction (STEMI) guidelines recommend
pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is …